1. Suliman, YA, Dobrota, R, Huscher, D, et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015; 67(12): 3256–3261.
Google Scholar | Crossref | Medline2. Steele, R, Hudson, M, Lo, E, et al. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012; 64(4): 519.
Google Scholar | Crossref | Medline3. Janardana, R, Nair, AM, Surin, AK, et al. Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease? Clin Rheumatol 2019; 38: 3179–3187.
Google Scholar | Crossref | Medline4. Steen, VD, Medsger, TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66(7): 940–944.
Google Scholar | Crossref | Medline5. Tyndall, AJ, Bannert, B, Vonk, M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis 2010; 69(10): 1809–1815.
Google Scholar | Crossref | Medline6. Tashkin, DP, Roth, MD, Clements, PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4(9): 708–719.
Google Scholar | Crossref | Medline7. Tzouvelekis, A, Galanopoulos, N, Bouros, E, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012; 2012: 143637.
Google Scholar | Crossref | Medline8. Shenoy, PD, Bavaliya, M, Sashidharan, S, et al. Cyclophospha-mide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther 2016; 18(1): 123.
Google Scholar | Crossref | Medline9. LeRoy, EC, Black, C, Fleischmajer, R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15(2): 202–205.
Google Scholar | Medline10. Miller, MR, Hankinson, J, Brusasco, V, et al. ATS/ERS task force. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
Google Scholar | Crossref | Medline11. Collard, H, Loyd, J, King, TE, et al. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med 2007; 101(9): 2011–2016.
Google Scholar | Crossref | Medline12. Kazerooni, EA, Martinez, FJ, Flint, A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin- section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169(4): 977–983.
Google Scholar | Crossref | Medline13. Goh, NS, Desai, SR, Veeraraghavan, S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 124854.
Google Scholar | Crossref14. Goldin, J, Elashoff, R, Kim, HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009; 136(5): 1333–1340.
Google Scholar | Crossref | Medline15. Khanna, D, Furst, DE, Hays, RD, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006; 65(10): 1325–1329.
Google Scholar | Crossref | Medline16. World Medical Association . World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191–2194.
Google Scholar | Crossref | Medline17. Kafaja, S, Clements, PJ, Wilhalme, H, et al. Reliability and minimal clinically important differences of FVC. Results from the scleroderma lung studies (SLS-I and SLS-II). Am J Respir Crit Care Med 2018; 197: 644–652.
Google Scholar | Crossref | Medline18. Tashkin, DP, Elashoff, R, Clements, PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25): 2655–2666.
Google Scholar | Crossref | Medline19. Roth, MD, Tseng, CH, Clements, PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63(9): 2797–2808.
Google Scholar | Crossref | Medline20. Khanna, D, Tseng, C, Farmani, N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63(10): 3078–3085.
Google Scholar | Crossref | Medline21. Goh, NS, Hoyles, RK, Denton, CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017; 69(8): 1670–1678.
Google Scholar | Crossref | Medline22. Katzenstein, AL, Fiorelli, RF. Non-specific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18: 136–147.
Google Scholar | Crossref | Medline